Abstract
Neoadjuvant therapy has been until recently indicated solely for enabling or facilitating surgical resection in primarily non-metastatic locally advanced breast cancer. Given the considerable financial and long-term issues of adjuvant trials, the accelerated approval of new drugs that proved effective in generating pCR in neoadjuvancy can be used for the adjuvant treatment.